52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Moderna Announces The European Commission's Approval Of Advance Purchase Agreement For Initial 80 Million Doses Of COVID-19 Vaccine
Moderna’S Covid-19 Vaccine Candidate Meets Its Primary Efficacy Endpoint In The First Interim Analysis Of The Phase 3 Cove Study
Moderna Has Completed Case Accrual For First Planned Interim Analysis Of Its Vaccine Against Covid-19
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
Biotechnology & Drugs
200 Technology Sq
Noubar B. Afeyan
Non-Executive Independent Chairman of the Board, Co-Founder
Chief Executive Officer, Director
David W. Meline
Chief Financial Officer
Chief Human Resource Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Pfizer Inc with partner BioNTech SE and Moderna Inc have released trial data showing their COVID-19 vaccines to be about 95% effective at preventing the illness, while AstraZeneca Plc this week said its vaccine could be up to 90% effective.
The European Union has struck a deal for up to 160 million doses of U.S. firm Moderna's COVID-19 vaccine candidate, the head of the European Commission said on Tuesday, taking the EU's potential stock of COVID-19 shots to nearly 2 billion.
The European Union has reached a deal with U.S. biotech firm Moderna for the supply of up to 160 million doses of its COVID-19 vaccine candidate, the president of the European Commission said on Tuesday.
The European Medicines Agency (EMA) could produce a scientific opinion on COVID-19 vaccines seeking regulatory approval by the end of the year in a best case scenario, the regulator's new chief was quoted as saying on Tuesday.
* PM Johnson: news demonstrates that pandemic will end (Adds UK PM Johnson)
The experimental COVID-19 vaccine developed by AstraZeneca and Oxford University would have a higher efficacy rate if trials were only measuring whether the shot prevents hospitalisation and severe disease, Oxford's vaccine chief said on Monday.
Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).
COVID-19 vaccines from Pfizer Inc and Moderna Inc could be ready for U.S. authorization and distribution within weeks, setting the stage for inoculation to begin as soon as this year, U.S. Health and Human Services Secretary Alex Azar said on Wednesday.
Air France-KLM is among airlines gearing up for the challenge of transporting millions of doses of temperature-sensitive COVID-19 vaccines in the midst of a travel slump.
Pfizer Inc's and Moderna Inc's COVID-19 vaccine candidates could be ready for U.S. authorization and distribution within weeks, setting the stage for widespread inoculation to begin as soon as this year, U.S. Health and Human Services Secretary Alex Azar said during a press...
Hong Kong stocks ended higher for a third straight session on Wednesday, with the automotive sector leading gains, as investors continued to cheer news of COVID-19 vaccine breakthroughs.
Airlines are scrambling to prepare ultra-cold shipping and storage facilities to transport COVID-19 vaccines developed by Pfizer and Moderna, whose doses, which require deep freezing, are likely to be among the first to be distributed.
Moderna Inc confirmed on Tuesday it had agreed to supply its COVID-19 vaccine candidate, mRNA-1273, to the United Kingdom starting from the beginning of March, as long as it succeeds in gaining local regulatory approval.
Moderna Inc said on Tuesday it agreed to supply its COVID-19 vaccine candidate, mRNA-1273, to the United Kingdom beginning March, if it is approved by the local regulatory authorities.
The Spanish government is in a "very advanced phase" of negotiations to buy vaccines against COVID-19 being developed by pharmaceutical firm Moderna, spokeswoman Maria Jesus Montero said on Tuesday. (Reporting by Andrey Khalip and Inti Landauro Editing by Ingrid Melander)
* Experts encouraged by Moderna results (Updates shares, adds detail)
* Currencies little moved on coronavirus vaccine progress * Growing unease about current rise in new infections * Traders in Asia focus on yuan's rise against greenback By Stanley White TOKYO, Nov 17 (Reuters) - The dollar steadied against most currencies on Tuesday as a...
The Australian dollar climbed to a one-week high on Tuesday, holding above key chart resistance of 73 U.S. cents, while its New Zealand peer was perched at a 19-month top as investor sentiment was boosted by coronavirus vaccine hopes.
* Currencies little moved on coronavirus vaccine progress * Growing unease about current rise in new infections * Traders in Asia focus on yuan's rise against greenback By Stanley White TOKYO, Nov 17 (Reuters) - The dollar nursed losses on Tuesday as a return of coronavirus...
* OPEC+ October supply cut compliance seen at 96%, sources say
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.